Literature DB >> 16757897

Prevention of immune responses to human erythropoietin in cynomolgus monkeys (Macaca fascicularis).

Naohide Ageyama1, Yutaka Hanazono, Hiroaki Shibata, Fumiko Ono, Takeyuki Nagashima, Yasuji Ueda, Yasuhiro Yoshikawa, Mamoru Hasegawa, Keiya Ozawa, Keiji Terao.   

Abstract

Genes and proteins of human origin are often administered to monkeys for research purposes, however, it can be difficult to obtain sufficient levels of the products in vivo due to immunological clearance. In this study, we showed that human erythropoietin (hEPO) induces generation of anti-hEPO antibody in cynomolgus macaques (n=2), although 92% of amino acid residues are common between the human and macaque EPO. The administered hEPO was thus eliminated from the animals. On the other hand, when an immunosuppressant, cyclosporin A (CyA), was administered (6 mg/kg) intramuscularly every other day in combination with hEPO (n=2), no anti-hEPO antibody was generated and high serum levels of hEPO were obtained during administration of hEPO, resulting in an increase in serum hemoglobin levels. No adverse effects associated with CyA were observed. Thus, CyA treatment is useful for prevention of immune responses associated with the administration of human proteins in monkeys.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757897     DOI: 10.1292/jvms.68.507

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  2 in total

1.  Establishment of two quantitative nested qPCR assays targeting the human EPO transgene.

Authors:  E W I Neuberger; I Perez; C Le Guiner; D Moser; T Ehlert; M Allais; P Moullier; P Simon; R O Snyder
Journal:  Gene Ther       Date:  2016-01-11       Impact factor: 5.250

2.  Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice.

Authors:  Matthieu Piccand; Juliana Bessa; Eginhard Schick; Claudia Senn; Carole Bourquin; Wolfgang F Richter
Journal:  AAPS J       Date:  2015-11-24       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.